Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Stem cell transplantation safe for patients with HIV-associated lymphoma

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

Stem cell transplantation safe for patients with HIV-associated lymphoma ( Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA )

Carfilzomib represents potent, effective addition to standard multiple myeloma...

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Post-transplant survival boosted by brentuximab vedotin in lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma...

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Children with aggressive leukaemia experiencing remission with T cell therapy

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA

Children with aggressive leukaemia experiencing remission with T cell therapy ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy

Prof Keith Stewart - Mayo Clinic, Scottsdale, USA

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )

Overall survival update from the BREAK-3 study

Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany

Overall survival update from the BREAK-3 study ( Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany )

Predicting the relapse of acute myeloid leukaemia with genetic screening

Dr Elaine Mardis - University of Washington, Washington, USA

Predicting the relapse of acute myeloid leukaemia with genetic screening ( Dr Elaine Mardis - University of Washington, Washington, USA )

Frontiers of pharmacokinetics and metabolism in cancer research

Prof Godefridus Peters - VU University Medical Center, Amsterdam, Netherlands

Frontiers of pharmacokinetics and metabolism in cancer research ( Prof Godefridus Peters - VU University Medical Center, Amsterdam, Netherlands )

ecancermedicalscience editor's choice for November 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for November 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients

Prof Elizabeth Swisher - University of Washington, Washington, USA

Biomarker for PARP inhibitor responsiveness in ovarian cancer patients ( Prof Elizabeth Swisher - University of Washington, Washington, USA )

New drug, ASP8273, shows response in Japanese patients with treatment-resistant...

Dr Haruyasu Murakami - Shizuoka Cancer Center, Shizuoka, Japan

New drug, ASP8273, shows response in Japanese patients with treatment-resistant non-small cell lung cancer ( Dr Haruyasu Murakami - Shizuoka Cancer Center, Shizuoka, Japan )

More from ecancer